Blueberry Therapeutics Meets Primary and Secondary Endpoints in Phase 2b Trial in Onychomycosis
13 nov. 2023 02h00 HE
|
Blueberry Therapeutics
Blueberry Therapeutics Meets Primary and Secondary Endpoints in Phase 2b Trial in Onychomycosis Primary endpoint (negative culture and/or clear nail growth) met with 83.3% response rate Secondary...
TLC to Present Phase 3 Data of TLC599 in Late-Breaking Abstracts Session at ACR
08 nov. 2023 04h54 HE
|
TLC
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Nov. 08, 2023 (GLOBE NEWSWIRE) -- TLC BioSciences (TLC), a late clinical-stage specialty pharmaceutical company developing novel nanomedicines to...
Tiziana Life Sciences Announces Allowance By FDA For At-Home Dosing Of Intranasal Foralumab For Multiple Sclerosis Treatment
18 oct. 2023 07h00 HE
|
Tiziana Life Sciences Ltd.
Patients In the Intermediate Size Patient Population Expanded Access (EA) Program Will Receive Intranasal Foralumab As Part of the At-Home Dosing InitiativeGreater Than 1 year Safety Exposure to...
Tiziana Life Sciences Announces Positive Six-Month Clinical Results in Multiple Sclerosis Patients Treated with Intranasal Foralumab
16 oct. 2023 07h00 HE
|
Tiziana Life Sciences Ltd.
Numeric improvements were seen across key multiple sclerosis measures, including the Modified Fatigue Impact Scale, Expanded Disability Status Scale, Timed 25-Foot Walk test, Pyramidal Scores and...
Tiziana Announces Positive Qualitative Six-Month PET Scan Results With Intranasal Foralumab Treating Multiple Sclerosis Patients Diagnosed With Non-Active Secondary Progressive MS (na-SPMS)
13 oct. 2023 07h00 HE
|
Tiziana Life Sciences Ltd.
Five out of six patients in FDA authorized Expanded Access Program are showing a qualitative reduction in microglia activation (a key biomarker being observed)Foralumab to advance into Phase 2 human...
[Latest] Global Mental Health Technology Market Size/Share Worth USD 18.9 Billion by 2032 at a 16% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
25 sept. 2023 18h30 HE
|
Custom Market Insights
Austin, TX, USA, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Mental Health Technology Market Size, Trends and Insights By Functionality...
OKYO Pharma Completes Enrollment in Phase 2 Clinical Trial of OK-101 to treat Dry Eye Disease
08 sept. 2023 07h00 HE
|
OKYO Pharma LTD
Full enrollment achieved on September 6th with a total of 240 patients enrolled in studyTop-line data planned for release in December 2023Phase 2 trial is designed as a potential registration trial,...
OKYO Pharma Achieves 90% Enrollment in 240-Patient Phase 2 Clinical Trial of OK-101 to treat Dry Eye Disease (“DED”)
30 août 2023 07h00 HE
|
OKYO Pharma LTD
Full enrollment anticipated by first week of SeptemberOKYO on schedule to release top-line data before end of 2023Phase 2 trial is designed as potential registration trial with pre-specified primary...
Clinical Chemistry Analyzers Market Size to Worth USD 24.8 BN by 2032
18 août 2023 10h45 HE
|
Precedence Research
Ottawa, Aug. 18, 2023 (GLOBE NEWSWIRE) -- The global clinical chemistry analyzers market size was valued at USD 14.63 billion in 2022. The advancement of the technologies behind clinical chemistry...
Disposable Endoscopes Market to hit USD 9.7 billion by 2032, says Global Market Insights Inc.
13 août 2023 21h30 HE
|
Global Market Insights Inc.
Selbyville, Delaware, Aug. 13, 2023 (GLOBE NEWSWIRE) -- Disposable Endoscopes Market size is expected to reach USD 9.7 billion by 2032. The industry is driven by technological advancements in the...